What is it?
Names, aliases and forms
Mechanisms of action
Proposed receptor signaling
6A pharmacology review describes several proposed pathways, with PPAR-alpha receptor activity as the most robustly supported. This mechanistic context does not establish healthy-user cognitive benefits.
Potential effects and evidence map
Grade C for nootropic use. One small placebo-controlled crossover study of formulated palmitoylethanolamide in healthy university students reported a memory-task signal; it is formulation-specific and needs independent replication.
One small six-week crossover study of formulated palmitoylethanolamide in healthy students reported fewer Paired Associates Learning errors than placebo.
Typical dosages and timing
The trial methods specify two capsules containing 300 mg active palmitoylethanolamide each, plus formulation excipients. The abstract calls this 700 mg/day of formulated product; the active amount is shown above. This is a study exposure, not a recommended healthy-user dose or proof that unformulated powder is equivalent.
Timing & effect horizon
Safety, side effects and risk profile
Mild, transient gastrointestinal symptoms were reported in a small PEA combination trial; attribution to PEA alone is uncertain.
Short-term oral trial tolerability is generally favorable. Reviews report mild transient gastrointestinal symptoms in a small combination trial and an isolated transient palpitation report with uncertain causality. Adverse-event collection was uneven; long-term, pregnancy/lactation and medication-interaction safety are not established. This rating applies to healthy-adult oral use over studied short courses, not every person, route or blend.
Legal and regulatory status
In the United States, as of 2026, FDA does not approve dietary supplements for safety and effectiveness before marketing. A supplement product making a disease claim is subject to drug regulation; this U.S. explanation does not establish other countries' rules.
How it compares
Palmitoylethanolamide and phenethylamine are distinct compounds. A listing labelled only PEA should be checked by full name before evidence or price comparison.
Practical buying and quality notes
- For powders, compare price per gram of palmitoylethanolamide; for capsules, check active milligrams per capsule and capsules per serving. A package total, capsule count or formulation weight is not an active dose. Verify the complete ingredient name and full formula on the merchant label before comparing offers.
- Standard powder, micronized, ultramicronized and enhanced-dispersion products can differ in formulation. Pain reviews do not establish healthy-user cognitive equivalence or universal superiority of a smaller particle size. Match the studied formulation before regarding equal labelled milligrams or a lower price as equivalent.6
FAQ
Does the healthy-adult study establish a general nootropic effect?
3No. It found a memory-task signal in one small formulated-product study. Independent replication and evidence in other healthy populations are needed before inferring a broad nootropic benefit.
Does the six-week study set a cycle length?
3No. The six-week trial length is an observation window, not evidence for a recommended cycle, acute effect duration, or long-term use plan.
What dosage is established for healthy-user cognition?
3No broadly validated healthy-user dose is established. The study exposure above was specific to an enhanced-dispersion formulation; a label serving or package weight should not be substituted for the active amount tested.
References
- PubChem Compound Summary for CID 4671, Palmitoylethanolamide.
- PubChem Compound Summary for CID 1001, Phenethylamine.
- Kim N, Parolin B, Renshaw D, et al. Formulated palmitoylethanolamide supplementation improves parameters of cognitive function and BDNF levels in young, healthy adults: a randomized cross-over trial. Nutrients. 2024;16:489.
- Lang-Illievich K, Klivinyi C, Lasser C, et al. Palmitoylethanolamide in chronic pain: systematic review and meta-analysis of double-blind randomized controlled trials. Nutrients. 2023;15:1350.
- Extended treatment with micron-size oral palmitoylethanolamide in chronic pain: systematic review and meta-analysis. Nutrients. 2024;16:1653.
- Gabrielsson L, Mattsson S, Fowler CJ. Palmitoylethanolamide for pain: pharmacokinetics, safety and efficacy. Br J Clin Pharmacol. 2016;82:932-942.
- U.S. Food and Drug Administration. FDA 101: Dietary Supplements. Accessed October 2026.
- Deb SK, Kim N, Parolin B, Renshaw D, Zariwala MG. The effects of formulated palmitoylethanolamide supplementation on indicators of stress and heart rate variability in female university students: a randomised cross-over trial. Front Nutr. 2025;12:1586409.